Benefit-sharing from DSI rests on the provider country's national framework. Where it requires bilateral benefit-sharing for DSI, those terms apply. Where it gives effect to the CBD multilateral mechanism, users of its publicly available DSI should share benefits through it: all users non-monetary benefits, as appropriate, and commercial users above set size thresholds also monetary contributions to the Cali Fund. Where it is silent on DSI, the position is not yet settled: check with the country's competent national authority, through the ABS service. Any terms agreed when the genetic resources were accessed still apply. Access and benefit-sharing questions are handled by the ABS service, not by the DataBank. Learn more →
Light/fluorescence microscopy of cells & tissues, and electron/cryo-EM imaging of macromolecular structures — a metadata catalog with a durable link back to the source archive, not a hosted image gallery. These are primary research datasets (often multi-GB to multi-TB), so this platform never downloads or stores the underlying imaging data itself. Datasets already in either source archive are ingested via accession paste/CSV at /mirroring by a Continental Admin (no automated harvesting — neither source archive supports geography-filterable search); a dataset not yet in either archive can instead be submitted directly below by any node operator, for Continental Admin review. Either way, whoever submits an accession or a self-submitted dataset is the one asserting African origin — this platform does not verify it.
Small-molecule Activation of TFEB Alleviates Niemann-Pick Disease Type C via Promoting Lysosomal Exocytosis and Biogenesis
BioImage Archive:S-BIAD1694 · 罗煜 (Zhejiang University of Technology) · Mycoplasma bradburyae
Niemann–Pick disease type C (NPC) is a devastating lysosomal storage disease characterized by abnormal cholesterol accumulation in lysosomes. Currently, there is no treatment for NPC. Transcription factor EB (TFEB), a member of the microphthalmia transcription factors (MiTF), has emerged as a master regulator of lysosomal function and promoted the clearance of substrates stored in cells. However, it is not known whether TFEB plays a role in cholesterol clearance in NPC disease. Here, we show that transgenic overexpression of TFEB, but not TFE3 (another member of MiTF family) facilitates cholesterol clearance in various NPC1 cell models. Pharmacological activation of TFEB by sulforaphane (SFN), a previously identified natural small-molecule TFEB agonist by us, can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. In NPC1 cells, SFN induces TFEB nuclear translocation via a ROS-Ca2+-calcineurin dependent but MTOR-independent pathway and upregulates the expression of TFEB-downstream genes, promoting lysosomal exocytosis and biogenesis. While genetic inhibition of TFEB abolishes the cholesterol clearance and exocytosis effect by SFN. In the NPC1 mouse model, SFN dephosphorylates/activates TFEB in brain and exhibits potent efficacy of rescuing the loss of Purkinje cells and body weight. Hence, pharmacological upregulating lysosome machinery via targeting TFEB represents a promising approach to treat NPC and related lysosomal storage diseases, and provides the possibility of TFEB agonists ie SFN as potential NPC therapeutic candidates.
Heterotrophic bacteria rapidly deplete essential macronutrients during growth and must navigate subsequent periods of growth arrest imposed by starvation. Nutrient limitations can be dynamic in nature, requiring ongoing regulatory adjustments involving new protein synthesis despite total biosynthetic activities being dramatically lower than during growth. Here, we have characterized the responses of the opportunistic pathogen Pseudomonas aeruginosa to prolonged starvation for carbon or nitrogen sources, and to transitions between these states. We find that most cells survive both types of starvation for more than a week and maintain low but robustly detectable levels of protein synthesis in the absence of growth. Nitrogen-starved cells are larger, make more proteins and retain fewer ribosomes than carbon-starved cells, indicating that distinct physiological strategies are adopted during the two starvation types. We found that the newly synthesized proteomes of each starvation type are distinct, although many of the most highly synthesized proteins are shared between both conditions. Interestingly, we observed a temporary burst of protein synthesis as cells were transitioned between the two starvation conditions, which may reflect active remodelling of the proteome during growth arrest. We also used transposon insertion sequencing to identify genes impacting fitness in both starvation conditions and during transitions between the two and found that a highly overlapping set of global regulators most strongly influenced survival. Combining these datasets, we highlight proteases and chaperones; flagellar motility; and the nitrogen-related phosphotransferase system as key fitness-impacting functions that are actively maintained by growth arrested Pseudomonas aeruginosa.
Chronic Pseudomonas aeruginosa lung infection is a major cause of morbidity and mortality in people with lung disease. Once established, infection is rarely eradicated and often persists despite prolonged antimicrobial therapy, but the mechanisms that support persistence in the human lung remain poorly understood. To define how P. aeruginosa occupies and adapts to diseased lung tissue, we applied host–pathogen spatial transcriptomics to explanted and resected lungs from people with Cystic Fibrosis (CF) and chronic obstructive pulmonary disease (COPD), mapping bacterial niches and transcriptional states in situ.
Two antagonistic response regulators control Pseudomonas aeruginosa polarization during mechanotaxis
BioImage Archive:S-BSST1007 · Marco Kühn (École Polytechnique Fédérale de Lausanne) · Pseudomonas amygdali pv. tabaci
Source data for figures corresponding to the study: Two antagonistic response regulators control Pseudomonas aeruginosa polarization during mechanotaxis. DOI: https://doi.org/10.15252/embj.2022112165
Microbial keratitis, infection of the cornea, cause by ExotoxinU (ExoU) strains of Pseudomonas aeruginosa have a poor clinical outcome and response to antimicrobials. ExoU, a phospholipase, is secreted directly into host cells, causing their lysis. A screen of 3,034 FDA-approved compounds identified zinc pyrithione (Zp), bismuth subcitrate (Bis), and polymyxin B (Pol) as lead inhibitors of ExoU selectively inhibiting it without affecting human PLA2s or bacterial viability. The compounds have distinct inhibitory mechanisms: Zp disrupted ExoU oligomerization and protein stability; Bis impaired phosphatidylinositol 4,5-bisphosphate-dependent membrane association; Pol directly inhibited catalysis via its lipid-peptide architecture. Compound combinations enhanced ExoU inhibition in vitro to nanomolar concentrations. In mammalian cells, Bis and Pol promoted lysosomal trafficking and degradation of ExoU. Using a high-throughput microscopy platform, we screened 53 P. aeruginosa keratitis isolates, confirming broad efficacy of these inhibitors in exoU⁺ strains. Therapeutic efficacy was evaluated in ex vivo porcine corneas, Galleria mellonella, and in vivo mouse keratitis models. Topical delivery of ExoU inhibitors, particularly in combination, significantly reduced corneal opacity, ulceration, and stromal damage in porcine corneas without affecting bacterial load. In Galleria, compound combinations significantly maintained larval health, improved larval survival and delayed mortality. In a mouse eye infection model, combinatorial treatment reduced disease severity and preserved tissue viability without altering bacterial burden. These findings validate ExoU as a druggable virulence factor and support the repurposing of these compounds as an anti-virulence strategy for the treatment of P. aeruginosa infections in humans and veterinary medicine.
LeishTag: Leishmania protein subcellular localisation through the life cycle
BioImage Archive:S-BIAD4306 · (University of Oxford) · Mycobacterium tuberculosis TKK_03_0050
LeishTag is a sub-project of the LeishGEM project aiming to determine where the proteins of the unicellular eukaryotic pathogen Leishmania mexicana localise within the cell. Endogenous tagging of proteins at the N or C terminus with mNG, targeting Leishmania-specific proteins in both the promastigote and amastigote life cycle stages which lack a Trypanosoma brucei ortholog or with low sequence similarity (<20%) than the T. brucei ortholog, thereby complementing the TrypTag project's annotations.
Small-molecule Activation of TFEB Alleviates Niemann-Pick Disease Type C via Promoting Lysosomal Exocytosis and Biogenesis
BioImage Archive:S-BIAD1694 · 罗煜 (Zhejiang University of Technology) · Mycoplasma bradburyae
Niemann–Pick disease type C (NPC) is a devastating lysosomal storage disease characterized by abnormal cholesterol accumulation in lysosomes. Currently, there is no treatment for NPC. Transcription factor EB (TFEB), a member of the microphthalmia transcription factors (MiTF), has emerged as a master regulator of lysosomal function and promoted the clearance of substrates stored in cells. However, it is not known whether TFEB plays a role in cholesterol clearance in NPC disease. Here, we show that transgenic overexpression of TFEB, but not TFE3 (another member of MiTF family) facilitates cholesterol clearance in various NPC1 cell models. Pharmacological activation of TFEB by sulforaphane (SFN), a previously identified natural small-molecule TFEB agonist by us, can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. In NPC1 cells, SFN induces TFEB nuclear translocation via a ROS-Ca2+-calcineurin dependent but MTOR-independent pathway and upregulates the expression of TFEB-downstream genes, promoting lysosomal exocytosis and biogenesis. While genetic inhibition of TFEB abolishes the cholesterol clearance and exocytosis effect by SFN. In the NPC1 mouse model, SFN dephosphorylates/activates TFEB in brain and exhibits potent efficacy of rescuing the loss of Purkinje cells and body weight. Hence, pharmacological upregulating lysosome machinery via targeting TFEB represents a promising approach to treat NPC and related lysosomal storage diseases, and provides the possibility of TFEB agonists ie SFN as potential NPC therapeutic candidates.
Heterotrimeric G proteins containing Gβ1γ2 subunits exhibit subtype-specific mobility differences in live cells
BioImage Archive:S-BIAD3061 · (BC AV ČR - Czech Academy of Sciences, Biology Centre) · Mycoplasma bradburyae
Heterotrimeric G proteins are key signal transducers in all eukaryotic cells. Anchored to the inner leaflet of the plasma membrane, they transmit and amplify extracellular chemical and physical signals downstream of G protein-coupled receptors. Despite numerous available studies, many biophysical aspects that regulate G protein signaling, including membrane mobility, remain poorly understood. Here, using single-molecule imaging, we show that different subtypes of heterotrimeric G proteins containing Gβ1γ2 subunits exhibit high diversity in their membrane mobility. We demonstrate that the nature of the Gα subunit plays a major role in defining the mobility of such heterotrimers. Our results indicate that heterotrimers containing Gα12 and Gα13 subunits exhibit markedly reduced mobility compared to those containing Gαi/o and Gαs subunits. These findings identify subtype-specific lateral membrane mobility of G proteins as a factor that can affect their signaling dynamics in living cells.